Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

Launched by MOCA CLINIC AND INSTITUTE · Jun 18, 2025

Keywords

ClinConnect Summary

This study is looking at a new way to screen people who may have early signs of Alzheimer’s disease or related memory problems. The goal is to use easy-to-do digital tests and simple blood tests to quickly find out who might benefit from treatments that could slow down the disease. By speeding up this process, doctors hope to start the right treatments sooner, giving patients a better chance to maintain their memory and daily functioning. The study will involve 500 people who have been referred to a special memory clinic in Montreal and will help create a tool to guide doctors in making faster and fairer decisions about who should get treatment.

People who might join this study are those who have memory or thinking concerns and have been referred to the MoCA Clinic, whether they are new patients or were last seen there over a year ago. Participants need to understand the study and agree to take part, and they must have a family member or close friend who knows them well and can provide helpful information during the study. Participants will complete digital memory tests and give blood samples, while their doctor will also assess their condition. The study includes regular check-ins and may help improve how future patients are diagnosed and treated more quickly. Certain people, such as those with other causes for memory problems or those already in other Alzheimer’s studies, won’t be eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must be referred to the MoCA Clinic; including both new patients and existing patients who have been seen \>1 year ago
• • Present with cognitive impairment or cognitive complaints.
• • Must have the ability to understand the purpose and risk of the Study and provide informed consent.
• • Must have an identified study partner (informant/care partner), who has frequent and sufficient contact with the participant to be able to provide accurate information about the participant's cognitive and functional abilities. The study partner must be available by phone to provide information to the study staff about the participant and agrees to attend one in-person visit at the MoCA Clinic which requires partner input. The study partner should be available for the duration of the study.
• Exclusion Criteria:
• • An established diagnosis (other than AD), that is a cause for a candidate's cognitive impairment (e.g. substance abuse, cerebrovascular conditions, Lewy body dementia, fronto-temporal dementia, recent head trauma).
• • Blood donation (1 unit) within 1 month prior to Study screening.
• • Inability to comply with requirements to complete essential components of the Study (e.g. visual impairment, severe kidney disease or ongoing kidney treatment)
• • Patients already enrolled in any clinical trial for AD at time of Study screening
• • Other unspecified reasons that, in the opinion of the Principal Investigator, or MoCA Clinic and Institute, make the candidate unsuitable for enrolment.